Publication Date:
2015-09-03
Description:
Key Points PR-104 represents a potential novel treatment for relapsed/refractory T-ALL. AKR1C3 expression could be used as a biomarker to select patients who may respond to PR-104 in prospective clinical trials.
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine
Permalink